贝伐珠单抗联合卡铂+多西他赛治疗卵巢癌和宫颈癌的临床疗效  

Clinical efficacy of bevacizumab combined with carboplatin and docetaxel in the treatment of ovarian cancer and cervical cancer

作　　者：贺伟平 黄春[2] 颜志婷 王文华[2] HE Weiping;HUANG Chun;YAN Zhiting;WANG Wenhua(Department of Pharmacy,Pingxiang People’s Hospital,Pingxiang 337055,Jiangxi,China;Department of Gynecology,Pingxiang People’s Hospital,Pingxiang 337055,Jiangxi,China)

机构地区：[1]萍乡市人民医院药学部,江西萍乡337055 [2]萍乡市人民医院妇科,江西萍乡337055

出　　处：《癌症进展》2023年第10期1078-1081,共4页Oncology Progress

基　　金：江西省卫生健康委科技计划项目(20204384、202212197)。

摘　　要：目的探讨贝伐珠单抗联合卡铂+多西他赛治疗卵巢癌和宫颈癌的临床疗效。方法根据治疗方式的不同将90例卵巢癌和宫颈癌患者分为对照组和观察组,每组45例,对照组患者给予卡铂+多西他赛治疗,观察组患者给予贝伐珠单抗联合卡铂+多西他赛治疗。比较两组患者临床疗效、血清肿瘤标志物[糖类抗原125(CA125)、肿瘤特异性生长因子(TSGF)、转化生长因子-β1(TGF-β1)、人附睾蛋白4(HE4)]水平、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+),计算CD4^(+)/CD8^(+))及不良反应发生情况。结果观察组患者的治疗总有效率为82.22%,明显高于对照组患者的51.11%,差异有统计学意义(P﹤0.01)。治疗后,两组患者血清CA125、TGF-β1、TSGF、HE4水平均低于本组治疗前,且观察组患者CA125、TGF-β1、TSGF、HE4水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,且观察组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。两组患者骨髓抑制、高血压、血小板减少、肝功能减退、恶心呕吐发生率比较,差异均无统计学意义(P﹥0.05)。结论贝伐珠单抗联合卡铂+多西他赛治疗卵巢癌和宫颈癌,可提高临床疗效,有效降低肿瘤标志物水平,改善患者免疫功能,且安全性较高。Objective To investigate the clinical efficacy of bevacizumab combined with carboplatin and docetaxel in the treatment of ovarian cancer and cervical cancer.Method A total of 90 patients with ovarian cancer and cervical cancer were divided into control group(n=45,treated with carboplatin+docetaxel)and observation group(n=45,treated with bevacizumab+carboplatin+docetaxel)according to different treatment.The clinical efficacy,serum tumor markers[carbohydrate antigen 125(CA125),tumor specific growth factor(TSGF),transforming growth factor-β1(TGF-β1)and human epididymis protein 4(HE4)],immune function indexes(CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+))and adverse reactions were compared between the two groups.Result The total effective rate of the observation group was 82.22%,significantly higher than the 51.11%of the control group,the difference was statistically significant(P<0.01).After treatment,the serum levels of CA125,TGF-β1,TSGF,HE4 were lower than those before the treatment,and the levels of CA125,TGF-β1,TSGF,HE4 in the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in both groups were higher than those before the treatment,while the levels of CD8^(+)were lower than those before the treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in the observation group were higher than those of the control group,the level of CD8^(+)was lower than that in the control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of bone marrow suppression,hypertension,thrombocytopenia,liver dysfunction,nausea and vomiting between the two groups(P>0.05).Conclusion Bevacizumab combined with carboplatin+docetaxel in the treatment of ovarian cancer and cervical cancer can improve the clinical efficacy,effectively reduce the levels of tumor markers,improve the immune function of patients,and has high safety.

关 键 词：卵巢癌 宫颈癌 贝伐珠单抗 卡铂 多西他赛 

分 类 号：R737.31[医药卫生—肿瘤] R737.33[医药卫生—临床医学]